Impact BioMedical, which is developing a portfolio of biomedical technologies, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering.
Operating mainly through subsidiary Global BioLife, the company funds the research and development of an intellectual property portfolio. It is currently focused on research in three main areas: development of a universal therapeutic drug platform, a new sugar substitute, and a multi-use fragrance.
The Houston, TX-based company was founded in 2017 and plans to list on the NYSE American but has not selected a symbol yet (RC ticker: MPCT.RC). Aegis Capital Corp. is the sole bookrunner on the deal. No pricing terms were disclosed.
